Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction

被引:36
|
作者
Murphy, Sean P. [1 ]
Prescott, Margaret F. [2 ]
Maisel, Alan S. [3 ]
Butler, Javed [4 ]
Pina, Ileana L. [5 ]
Felker, G. Michael [6 ,7 ]
Ward, Jonathan H. [2 ]
Williamson, Kristin M. [2 ]
Camacho, Alexander [1 ]
Kandanelly, Ritvik R. [1 ]
Solomon, Scott D. [8 ,9 ]
Januzzi, James L. [1 ,9 ,10 ]
机构
[1] Massachusetts Gen Hosp, Yawkey 5984,55 Fruit St, Boston, MA 02114 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[4] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA
[5] Detroit Med Ctr, Detroit, MI USA
[6] Duke Univ, Med Ctr, Durham, NC USA
[7] Duke Clin Res Inst, Durham, NC USA
[8] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[9] Harvard Med Sch, Boston, MA 02115 USA
[10] Baim Inst Clin Res, Boston, MA USA
关键词
biomarkers; echocardiography; heart failure; prospective studies; valsartan; SOLUBLE ST2; NATRIURETIC PEPTIDE; TROPONIN-T; PROGNOSTIC VALUE; ENALAPRIL; THERAPY;
D O I
10.1161/CIRCHEARTFAILURE.120.008410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Sacubitril/valsartan (S/V) treatment is associated with reverse cardiac remodeling and reductions in biomarkers reflecting ventricular wall stress and myocardial injury, such as NT-proBNP (N-terminal pro-B-type natriuretic peptide), hscTnT (high-sensitivity cardiac troponin T), and soluble suppressor of tumorigenicity 2 (sST2). How longitudinal changes in these biomarkers analyzed collectively are associated with cardiac remodeling in patients with heart failure with reduced ejection fraction treated with S/V is uncertain. METHODS: In a prospective study of S/V in patients with heart failure with reduced ejection fraction, this prespecified exploratory analysis included patients with serially collected biomarkers and echocardiographic measures of cardiac remodeling through 12 months of treatment. A multivariate latent growth curve model assessed associations between simultaneous changes in biomarkers and left ventricular ejection fraction and left atrial volume index. RESULTS: Seven hundred fifteen out of 794 total study participants were included (mean age 65 years, 73% male). Mean baseline left ventricular ejection fraction and left atrial volume index were 29% and 40 mL/m(2), respectively. Adjusted geometric mean baseline concentrations for biomarkers included NT-proBNP of 649 pg/mL, hs-cTnT of 15.9 ng/ L, and sST2 of 24.7 ng/mL. Following initiation of S/V, circulating concentrations of NT-proBNP, hs-cTnT, and sST2 significantly decreased within 30 days and remained significantly different than baseline at all subsequent timepoints. From baseline to month 12, decreases in adjusted biomarker concentrations averaged -27.9% (95% CI, -35.1% to -20.7%; P<0.001) for NT-proBNP; -6.7% (95% CI, -8.8% to -4.7%; P<0.001) for hs-cTnT; and -1.6% (95% CI, -2.9% to -0.4%; P<0.001) for sST2. NT-proBNP concentrations were predictive of later changes in hs-cTnT. The magnitude of reductions in NT-proBNP and hs-cTnT concentrations associated with improvements in left ventricular ejection fraction and left atrial volume index. There was no association between changes in sST2 and changes in other measures. CONCLUSIONS: Following initiation of S/V, NT-proBNP, hs-cTnT, and sST2 concentrations decreased significantly. Longitudinal changes in NT-proBNP and hs-cTnT together associated with left atrial and left ventricular reverse remodeling.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Efficacy of angiotensin–neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction
    Laura Ferrari
    Simona Sada
    Internal and Emergency Medicine, 2015, 10 : 369 - 371
  • [42] Prospective Monitoring of the Effectiveness and Safety of Angiotensin Receptor-Neprilysin Inhibitor Among Older Adults with Heart Failure with Reduced Ejection Fraction and Frailty
    Ko, D.
    Lin, K. J.
    Glynn, R. J.
    Cheng, S.
    Tsacogianis, T.
    Kim, D.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 : S225 - S225
  • [43] Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy
    In-Cheol Kim
    Jong-Chan Youn
    Se Yong Jang
    Sang Eun Lee
    Hyun-Jai Cho
    Jin-Oh Choi
    Ju-Hee Lee
    Kyung-Hee Kim
    Sun Hwa Lee
    Kye Hun Kim
    Jong Min Lee
    Byung-Su Yoo
    Scientific Reports, 12
  • [44] Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy
    Kim, In-Cheol
    Youn, Jong-Chan
    Jang, Se Yong
    Lee, Sang Eun
    Cho, Hyun-Jai
    Choi, Jin-Oh
    Lee, Ju-Hee
    Kim, Kyung-Hee
    Lee, Sun Hwa
    Kim, Kye Hun
    Lee, Jong Min
    Yoo, Byung-Su
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [45] Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
    Lewis, Gavin A.
    Schelbert, Erik B.
    Miller, Christopher A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1182 - 1182
  • [46] Long-Term Effects of Angiotensin Receptor-Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
    Poglajen, Gregor
    Anzic-Drofenik, Ajda
    Zemljic, Gregor
    Frljak, Sabina
    Cerar, Andraz
    Okrajsek, Renata
    Sebestjen, Miran
    Vrtovec, Bojan
    DIAGNOSTICS, 2020, 10 (08)
  • [47] Real world clinical outcomes of angiotensin receptor-neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction: A Malaysian experience
    Ghazi, A. Mohd
    Teoh, C. K.
    Thum, C. H.
    Teh, K. C.
    Lee, T. J.
    Ong, S. H.
    Fegade, M.
    Rahim, A. A. Abdul
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 345 : 6 - 7
  • [48] PROSPECTIVE MONITORING OF THE EFFECTIVENESS AND SAFETY OF ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR AMONG OLDER ADULTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND FRAILTY
    Ko, Darae
    Lin, Kueiyu Joshua
    Glynn, Robert J.
    Cheng, Susan
    Patorno, Elisabetta
    Tsacogianis, Theodore
    Kim, Dae Hyun
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 474 - 474
  • [49] Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
    Solomon, S. D.
    McMurray, J. J. V.
    Anand, I. S.
    Ge, J.
    Lam, C. S. P.
    Maggioni, A. P.
    Martinez, F.
    Packer, M.
    Pfeffer, M. A.
    Pieske, B.
    Redfield, M. M.
    Rouleau, J. L.
    van Veldhuisen, D. J.
    Zannad, F.
    Zile, M. R.
    Desai, A. S.
    Claggett, B.
    Jhund, P. S.
    Boytsov, S. A.
    Comin-Colet, J.
    Cleland, J.
    Dungen, H. -D.
    Goncalvesova, E.
    Katova, T.
    Kerr Saraiva, J. F.
    Lelonek, M.
    Merkely, B.
    Senni, M.
    Shah, S. J.
    Zhou, J.
    Rizkala, A. R.
    Gong, J.
    Shi, V. C.
    Lefkowitz, M. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17): : 1609 - 1620
  • [50] Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction
    Zhang, Yue
    Yuan, Meng
    Suo, Ya
    Yang, Qian
    Shao, Shuai
    Li, Ying
    Wang, Yuanyuan
    Bao, Qiankun
    Liu, Tong
    Li, Guangping
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2022, 49 (08) : 848 - 857